The Human-in-the-Loop Myth: How AI Insurance Denials Get Rubber-Stamped

The legal argument starts with a reassuring claim: a human reviewed your case. That claim shows up in appeal responses, in court filings, and in regulatory submissions. It is also, when you look at how the process is actually structured, largely a contractual formality. Here is what the operational design looks like in practice. Utilization management companies — firms that insurers hire to evaluate whether a procedure, stay, or medication is medically necessary — contract with clinical peer reviewers, typically nurses or physicians, to make adverse determinations. The contracts specify that a licensed professional must sign off on denials. That satisfies the "human-in-the-loop" requirement in state regulations and, insurers argue, satisfies due process standards that courts have applied to administrative benefit determinations. But the process does not give those reviewers what they would need to genuinely re-adjudicate a claim. The reviewer receives an AI-generated summary — a condensed clinical narrative produced by an algorithm trained on population-level protocols. They do not receive the full medical record, the treating physician's notes, or the treating physician's reasoning. They have, by published accounts from former reviewers and by settlement documents in several pending cases, between 90 seconds and a few minutes to review the summary, assess whether it aligns with their clinical judgment, and sign off or escalate. The incentive structure is not ambiguous. Revoking an AI denial — sending a case back for a second review — triggers a flags-and-review workflow that counts against reviewer productivity metrics. Escalation rates are tracked. Denial rates are tracked. A reviewer who consistently overrides AI output generates administrative costs and, over time, contract renewal risk. The contractual safeguard is real. The functional safeguard it was designed to create is not. Courts have begun engaging with this gap, but the doctrine is still forming. The NTIA's 2024 AI Accountability Report identified "accountability inputs" — documentation showing who saw what, when, and what they were empowered to do — as a critical evidentiary need for harmed individuals trying to trace causal chains. That framework helps plaintiffs survive initial pleading thresholds, but it does not yet resolve the harder question: if the human reviewer was structurally prevented from independently evaluating the claim, what does "a human reviewed it" actually establish? Some states have moved to close the gap legislatively. Illinois requires that a licensed clinical peer make adverse medical necessity determinations and explicitly prohibits sole algorithmic automated processes for those decisions. Alabama mandates that AI-assisted determinations be based on individual clinical history rather than population norms. These are meaningful constraints, but they operate at the state level against a system designed to be federally contractual and operationally uniform. At the federal level, the EU AI Act creates a tiered risk framework with mandatory liability provisions for high-stakes AI systems, effective August 2, 2026. The United States has no equivalent comprehensive framework. The regulatory landscape governing AI-assisted claims decisions in most of the country remains a patchwork of state insurance regulations, ERISA overlay for employer-sponsored plans, and administrative procedure act standards written before algorithmic decision-making existed. The practical result is that a denied claimant appealing in Arizona faces different evidentiary burdens and different procedural protections than one appealing in Illinois, and neither framework clearly addresses whether a reviewer who was not given the information needed to reverse the denial bears legal responsibility for the denial itself. What is shifting, however, is the defendant landscape. Fault-based liability theories — negligence, breach of warranty, consumer protection claims — are increasingly being directed not only at insurers and utilization management companies but at the companies that built and deployed the AI systems. That matters for individuals trying to recover actual damages: a named developer with regulatory exposure and assets represents a materially different legal target than a utilization management company with a rotating panel of 90-second reviewers. The structural argument does not depend on any single case or regulatory development. It stands on the contractual design of the review process, the documented incentive structure inside it, and the gap between what human oversight is required to do and what it is operationally equipped to do. That gap is real, it is documented, and it is not resolved by the fact that a licensed professional's signature appears on the denial letter.